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ABSTRACT

ROLE OF NON-MUSCLE MYOSIN II IN Hs578T/Hs578Ts(i)8 TRIPLE NEGATIVE
BREAST CANCER PROGRESSION

SHIMARA GUNAWARDANA

2018
Loss of cell-cell adhesion and migration are prerequisites for the formation of
metastases. These events are mediated by changes in the actomyosin cytoskeleton. Nonmuscle myosin II (NMII) belongs to the myosin superfamily of motor proteins which
binds to actin and controls actin cross-linking and contraction, however its role and
regulation in cell-adhesion and migration remains poorly understood.
In this study, we report that associations of α5β1integrin receptors and Ncadherins with NMII isoforms NM-IIA and NMII-B correlate with increased cell-cell
adhesion and reduced migratory behavior of the parental Hs578T cells of the
Hs578T/Hs578Ts(i)8 triple-negative breast cancer progression model. Using blebbistatin,
a pharmacological inhibitor of NMII ATPase activity which decreases non-muscle
myosin II contraction, on Hs578T cells induced loss of cell-cell adhesion and increased
migration which was comparable to the behavior of the invasive Hs578Ts(i)8 subclone.
The blebbistatin-mediated NMII inhibition in Hs578T cells not only stimulated the
polymerization of F-actin, but also the formation of highly organized F-actin, myosin

xii
The blebbistatin-mediated NMII inhibition in Hs578T cells not only stimulated the
polymerization of F-actin, but also the formation of highly organized F-actin, myosin
fibers and actin-rich protrusions with more nascent paxillin and talin-1 based focal
adhesion complexes, while reducing N-cadherin and α5β1 integrin receptor clustering at
cell-cell junctions. These findings provide novel insights into the role of NMII in the
regulation of cell-cell adhesion and migration by linking N-cadherin and integrins to the
actomyosin cytoskeleton to maintain stable cell-cell adhesion complexes.
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Chapter 1. Introduction
Alterations in membrane organization and signaling pathways responsible for
enhanced migration in metastatic cancers are not clearly understood. Elucidating these
molecular mechanisms could uncover potential molecular targets for effective cancer
therapeutics and early diagnosis of metastatic cancers.
1.1. Cancer progression
1.1.1 Introduction
Cancer manifests as an aberrant growth of cells due to genetic or epigenetic
modifications. Consequently, genes that normally govern cellular processes such as
proliferation, apoptosis and migration are upregulated and genes that normally suppress
such processes are downregulated1. A cell with an initial mutation undergoes further
mutations followed by selective expansion to establish a tumor mass with high genetic
instability (Fig. 1.1)2.

Figure 1.1 Tumor progression and mutations

Benign tumors consist of a mass of tumor cells at the site of origin which can be
removed successfully through surgical resection. However, not all cells remain at the site
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of the primary tumor as some move away to distal tissues and form secondary tumors3.
Micrometastases are often not detected at the time of disease diagnosis due to the low
sensitivity of traditional detection methods. When undetected, micrometastases
proliferate over time and form secondary tumors that are unable to be surgically
extracted; therefore, metastasis is the major cause of deaths in cancer patients. Metastasis
is a multi-step process including loss of cell-cell adhesion, invasion to adjacent stroma,
intravasation, movement through capillaries, evasion of the immune system, arrest as
single cells or clusters, extravasation through the endothelium, and formation of a
secondary tumor (Figure 1.2). Furthermore, alterations in cell-cell adhesion and cellextracellular matrix (ECM) adhesion are prerequisites for the formation of metastases 2, 4.

Figure 1.2. Cancer metastasis
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1.1.2 Cellular processes associated with metastasis
1.1.2.1 Changes in cell adhesion
Cell adhesion involves interactions between individual cells and cells to their
surrounding matrix through cell adhesion molecules (CAMs). These adhesive interactions
act as a link between the cellular cytoskeleton and the environment, which provides the
necessary stimuli to activate signaling pathways for proliferation and migration. CAMs
are transmembrane glycoproteins, each composed of an intracellular signaling domain
and an extracellular binding domain. This group of proteins typically consist of calciumdependent molecules including cadherins and integrins, the calcium-independent
immunoglobulin superfamily, and receptors for lymphocytes such as CD445. Homotypic
and heterotypic adhesions involve interaction between cells of the same type and
interactions between cells of different types respectively. They can be further categorized
into either homophilic (between identical molecules) or heterophilic (between different
molecules) adhesions6.
Although cell attachment plays a critical role in the survival of normal epithelial
cells, dissemination of cells from the primary tumor is necessary to initiate the metastatic
cascade. In cells leaving their original tumor microenvironment, cell detachment induces
programmed cell death known as anoikis, through the activation of apoptotic and
mitochondrial signaling cascades. However, metastatic cancers circumvent anoikis by
undergoing numerous biochemical and phenotypic modifications allowing them to
assume aberrant cell survival properties5.
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Cell-cell adhesion
Important structures in the maintenance of cell-cell adhesion are gap junctions,
tight junctions and adherens junctions. Among these, adherens junctions offer the
strongest adhesion in epithelial cells due to the cadherin superfamily (also found in
desmosomes)7. Cadherins are transmembrane glycoproteins that in the presence of Ca2+
form stable homophilic homotypic cell-cell interactions. Cadherins are key players in
tissue morphogenesis during development and in the maintenance of tissue architecture in
mature organisms. Furthermore, while providing mechanical support to tissues and
organs, cadherins also mediate membrane trafficking, growth factor signaling and
cytoskeletal remodeling. Classical cadherins consist of a N-terminal ectodomain with five
highly conserved repeats that mediate calcium-based homophilic interactions in trans
position, a single spanning transmembrane domain, and a C-terminal intracellular
catenin-binding domain that interacts with the actin cytoskeleton or intermediate
filaments via α-, β-, γ- or p120 catenins (Figure 1.3.)8-9.

Figure 1.3. Cadherin structure

There are over 20 members in the cadherin superfamily known to mediate
adhesion in a tissue specific manner. Among these, E-cadherin is the most extensively
studied molecule and is vital for the maintenance of cell polarity, organization and
contact-inhibition in epithelial cells7. Downregulation of E-cadherin is associated with
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the loss of epithelial morphology and the epithelial-to-mesenchymal transition (EMT)
observed in metastatic breast, colon, and prostate cancers. Reconstituted expression of Ecadherin in E-cadherin deficient cells has shown to rescue the invasive phenotype;
therefore, E-cadherin is classified as a tumor suppressor. N(neural)-cadherin, found in
stromal cells such as fibroblast, is concomitantly upregulated during E-cadherin
downregulation in EMT and expressed in metastatic cancers of epithelial origin5. Its
original role in the nervous system range from regulation of axonal development to
synapse formation, and studies have shown a possible role in vascularization of early
neuroectoderm prior to tissue differentiation. In small-cell lung cancer, a high correlation
of cadherin expression and vascularization suggests an angiogenic role for N-cadherin in
disease progression. E-to-N cadherin switching is associated with a fibroblast-like
phenotype responsible for invasion and migration of certain breast carcinomas. De novo
expression of N-cadherin is thought to assist tumor cell adherence to surrounding stroma
and thereby facilitates the formation of metastases10. Although aberrant N-cadherin
expression is commonly associated with tumor metastatic potential, unchanged or
downregulated expression levels have also been observed in several invasive cancers.
In osteosarcoma, N-cadherin acts as a tumor suppressor by inhibiting cell motility,
while in glioblastoma, expression remains unchanged and is downregulated during
relapse stages of the disease. Therefore, N-cadherin-based metastasis vary in a disease
stage and in a tissue specific manner10.
A multitude of molecules form complexes with the cytoplasmic domain of Ncadherin to alter its activity and downstream effectors. One such group is the Rho
family of small guanosine triphosphatases (GTPases) that belongs to the Ras
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superfamily and behaves as molecular switches alternating between inactive and active
forms. GTPase activating proteins (GAPs) facilitate the intrinsic GTPase activity to
form the GDP-bound inactive form, while guanine exchange factors (GEFs) associate
with Rho GTPases to form the GTP-bound active form11. In fibroblasts cells, plateletderived growth factor receptor (PDGF-R) mediated association of p120catenin,
RhoGAP, and N-cadherin have been observed in the formation of dorsal ruffles.
Membrane ruffling is a Rho GTPase directed actin polymerization event in early cell
stretching and an important cellular change to initiate migration12. Additionally,
spatiotemporal activity of Rho GTPases has shown to play a role in the maintenance of
junctional integrity13. Furthermore, N-cadherin based signaling also involves protease
shedding of the cadherin extracellular domain, and the translocation of the C-terminal
fragment to the nucleus for transcriptional regulation of genes involved in growth and
differentiation 12.
Cell-matrix adhesion
In higher organisms, the ECM encapsulates tissues and organs in order to provide
mechanical support, protection, and compartmentalization. The ECM is composed of a
variety of molecules including fibrous proteins, glycoproteins, proteoglycans and
carbohydrates that upon membrane binding can activate signaling pathways that govern
cell survival, growth, differentiation, and homeostasis. Cell-matrix adhesion is primarily
mediated by Integrins, which are heterodimeric transmembrane proteins composed of
non-covalently bound α and β subunits. Integrins are versatile membrane receptors with
18 α subunits and 8 β subunits identified to form 24 integrin heterodimers so far in
mammals, with each heterodimer binding to a unique matrix14. For example, integrin

7
α5β1 or α4β1 can specifically bind to fibronectin, while integrin α6β1 can bind to
laminin. The extracellular domain of integrin receptors binds to the ECM, divalent
cations, or endothelial ligands such as vascular cell adhesion molecule 1 (VCAM-1) of
the immunoglobulin superfamily, while the short intracellular domain binds to the actin
cytoskeleton via a multimeric protein complex. As a result of binding to both
extracellular and intracellular components, integrins are able to relay bidirectional
tension forces and molecular signaling15. Upon ECM binding, integrins transmit
information into the cells (outside-in signaling) and can regulate intracellular dynamics
like cytoskeletal remodeling. Additionally, intracellular signaling can influence an
integrin receptor’s structural conformation and ligand-binding affinity (inside-out
signaling) and thereby alter adhesion to the ECM16. Activation upon ligand binding
promotes integrin clustering that initiates the recruitment of binding proteins, adaptor
proteins, and various signaling molecules to form focal adhesion (FA) complexes at
these sites (Figure1.4)16.

Figure 1.4. Integrin clustering

FAs link the actin cytoskeleton to the surrounding matrix and enable the
mechanical transduction of cellular forces and formation of cell protrusions, two pivotal
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events in migration. In FAs, signaling molecules such as focal adhesion kinase (FAK)
have been observed to phosphorylate adapter molecules like paxillin and assist full GEF
docking for Rho activation, which regulates actin remodeling, cell polarity, and myosin
contraction essential for cell movement17.
Although adhesion is critical for cell survival, tumor cells utilize aberrant
adhesion and signaling mechanisms to invade local stroma, vasculature, and the ECM of
distal tissues. Tumor cells achieve this endeavor by altering the integrin repertoire,
expression levels, and ligand affinity, allowing migrating cells to recognize various
extracellular matrices, enabling alternative signaling and survival mechanisms. It has
been reported that in metastatic melanomas, integrin α2β1 and α3β1 are highly expressed
relative to primary tumors which thereby allow cell migration on laminin and type IV
collagen18. Aside from providing physical adhesion and signaling for cytoskeletal
remodeling, integrins are also implicated in facilitating metastasis by degradation of the
ECM. Integrin α5β1 association with fibronectin has been shown to activate various
signaling pathways to mediate matrix metalloprotease (MMP) -1 and MMP-2
collagenase-based matrix degradation in breast cancer19. Furthermore, integrin crosstalk
with cadherin cell-cell adhesion molecules has been reported in patient biopsies of a
highly invasive brain tumor variant, glioblastoma multiforme suggesting that careful
coordination of cell-cell and cell-matrix adhesion dynamics are essential for the
invasive phenotype in cancer20.
1.1.3 Migration and cytoskeletal re-organization
1.1.3.1 Tumor cell motility
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Cellular locomotion, a hallmark of a living organisms, is essential in
embryogenesis, wound healing, angiogenesis and immune surveillance and is a cellular
response to external physical and biochemical stimuli21. Similarly, cancer cells also
respond to environmental cues and reorganize the actin cytoskeletal for invasion and
migration. The ECM and tumor microenvironment components bind to integrins or other
surface receptors and transduce downstream signaling, independently or in
transactivation in order to regulate actin dynamics22. Integrins are fundamental in cancer
cell migration as they form adhesion complexes that serve as divergence points for a
number of signaling pathways and drive FA maturation, proteolytic ECM degradation,
and cytoskeleton remodeling23.
Cancer metastasis includes several modes of cell migration; single cell twodimensional (2D) mesenchymal migration and/or 3D amoeboid migration, and collective
cell migration that involves a cohort of tightly interconnected motile cells24. However, as
tumor cells display differentially regulated modes based on cell type and its tumor
microenvironment, one specific approach of studying migration dynamics is not feasible.
In the commonly studied 2D motility, cells initiate migration by promoting polarization
and membrane protrusions at the leading edge (front of the cell). Actin polymerization
within a few microns of the leading-edge pushes against the cell membrane forming
protrusive elements like lamellipodia, filopodia, and invadopodia, which brings cell
surface proteins like integrins in contact with the underlying substratum21. Integrin-ECM
interactions drive FA formation and protrusion stabilization, establishing an asymmetric
arrangement of adhesion complexes between the front and the back of the cell. Adhesion
complexes at the leading edge originate as dot-like nascent adhesions that mature into
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larger FAs along actin filaments or breakdown and turnover (recycled) into new adhesive
complexes for continuation of the cyclic migration process17. Bipolar myosin filaments
crosslink between actin filaments and terminate at focal adhesions, and myosin
contraction facilitate translocation of the cell body forward, simultaneously dragging the
trailing edge (back of the cell) in the direction of migration. Adhesion complexes at the
trailing edge are broken down as the cell’s rear detaches from the ECM and new adhesive
complexes are reformed (Figure 1.5)24-25.
Myosin contraction is also implicated in maturation and stabilization of FAs
either by tension-dependent mechanisms or by regulation of the actin retrograde flow via
actin crosslinking26. Therefore, cells with low myosin contractility show higher number
of nascent adhesions whiles cells with high myosin contractility show less nascent
adhesion and more mature FAs27. Furthermore, in motile cells an inverse correlation
between migration speed and size of FAs have been observed28.

Figure 1.5. Events in cell migration
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1.1.3.2 Actin polymerization
Actin, a ubiquitous protein in eukaryotes plays a central role in cytoskeleton
dynamics and drives polarization, cell division, migration and vesicular trafficking25.
Three predominant isoforms of actin discovered in vertebrates are the β and γ isoforms
present in smooth muscle and non-muscle and the α isoform found in smooth, skeletal
and cardiac muscle. In cells, actin is found in globular (G-actin) or filamentous (F-actin)
forms, and G-actin nucleation initiates polymerization into a double-stranded helix that
interacts with actin-binding proteins (ABPs). G-actin in its ATP-bound state associates
into the fast-growing (+) end of the actin filament using its ATPase activity while F-actin
in its GDP-bound state dissociates at the pointed (-) end. This polymerization/depolymerization event has been classified as the actin-treadmill. ABPs associate with actin
and regulate its functions by severing filaments, obstructing monomer association, and
capping of barbed/pointed ends29. Since tumor cells manifest aberrant migratory activity
through altered cytoskeleton reorganization, actin regulation by ABPs and associated
signaling pathways are of utmost importance in understanding disease progression.
Cell migration initiates with membrane stretching and subsequent formation of
protrusive, actin rich structures at the plasma membrane. Lamellipodia, a thin fan-like
structure devoid of cellular organelles at the leading edge, supports migration by adhering
to the substratum and generating traction forces. The lamellipodia at the leading edge of
moving cells display a dendritic arrangement of actin filaments maintained by dynamic
actin polymerization/de-polymerization in a spatiotemporal manner. Podosomes and
filopodia, morphologically similar to blebs and finger-like protrusions in the lamellipodia
respectively, consist of an actin rich mid-region and a ring-like array of talin-1 and
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vinculin adhesive molecules that assist in sensing environmental cues for directional
migration and also provide additional traction forces for cellular motility21.
Rho GTPases are considered the master regulators of actin dynamics driving
distinct signaling pathways for various structural alterations required for migration and
invasion, their aberrant activity is implicated in abnormal actin remodeling in cancer
metastasis30. Although specific Rho GTPases have been studied in relation to cancer
metastasis, and their exact roles or local activities in mesenchymal migration are not
clearly understood. Cell migration is controlled by Rho GTPases via Wiskott-Aldrich
syndrome proteins (WASP) by mediating formation of lamellipodia at the leading edge.
WASP family proteins, downstream effectors of Rho and Rac signaling, activate actinregulating protein (Arp) 2/3 complexes that promote actin filament nucleation, and
severing for the formation of new actin side-branches. Furthermore, upregulation of
WASP/Arp2/3 activity has been observed in the invasive cancer phenotype, suggesting
the importance of actin remodeling in tumor migration25. Cofilin-1, a key regulator of
actin dynamics can also sever actin filaments or nucleate existing filaments and induce
actin polymerization for lamellipodia formation. Cofilin in return is regulated by various
upstream kinases like LIM domain kinase (LIMK) 1 and 2 and testis expressed serine
(TES) kinases 1 and 2 that phosphorylate the serine 3 residue of cofilin and inactivates
cofilin activity. Suppressing cofilin activity by siRNA silencing or by upregulating LIMK
activity has been shown to decrease motility of cancer cells, while overexpression of
active cofilin stimulates the metastatic behavior of cervical, colon, and liver cancers.
Given that actin cytoskeleton remodeling takes place under tight regulation of
cofilin/LIMK activity in a spatiotemporal manner, a delicate balance between the
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molecular players is crucial for successful migration. A disruption in this equilibrium by
an over-activation of cofilin or LIMK activity has been observed to change cell
motility21.
1.1.3.3 Myosin contraction
The myosin superfamily of motor proteins is best known for their association with
actin and the formation of force generating machineries in sarcomeres of muscle tissue.
To date, about 13 different classes of myosin have been identified responsible for a wide
range of cellular contractile functions and among these myosin II, also known as
conventional myosin is the most widely studied class in eukaryotes31. A similar class to
myosin II is the non-muscle myosin II (NMII), which plays a fundamental role in cellular
processes like cell adhesion, migration, and cytokinesis in mammals. NMII is a
hexameric protein, consisting of two heavy chains, two regulatory light chains (RLC),
and two essential light chains (ELC) that together form bipolar filaments that slide
between actin bundles to bring about contraction. The heavy chain encompasses actin and
an adenosine triphosphate (ATP) binding head domain, ELC and RLC binding neck
domain, and a tail domain that forms a helical homodimer. In this class of myosins, three
isoforms NMII-A, NMII-B, and NMII-C have been identified based on the myosin heavy
chain sequences encoded by MYH9, MYH10, and MYH14 genes respectively. NMII’s
contractile activity is modulated by phosphorylation of specific amino acid residues
(Ser19/Thr18) on the RLC. For example, NMII when de-phosphorylated assumes a
functionally inactive, folded 10S conformation and upon phosphorylation of Ser19 it
adopts an active, unfolded 6S conformation, which upon further Thr18 phosphorylation
augments actin binding and ATPase activity for contraction (Figure 1.6a)32. Furthermore,
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NMII association into bipolar filaments is downregulated by phosphorylation of Ser1943
in NMII-A and several serine residues in NMII-B in the heavy chain tail domains (Figure
1.6b)33-34.

Figure 1.6. a) NMII structure and activation b) NMII filament assembly with actin

Several commonly studied serine/threonine kinases in relation to RLC
phosphorylation are Rho-associated coiled-coil containing kinase (ROCK), myosin light
chain kinase (MLCK), and leucine zipper-interacting protein kinase (ZIPK)35. Calcium
and calmodulin-association with MLCK activates its kinase function, which specifically
phosphorylates NMII RLC. RhoGEF/RhoGAP mediated activity of Rho GTPases (Rac,
cdc42, RhoA, and RhoC) are implicated in the activation of ROCK and subsequent
myosin stress fiber formation. Upon Rho activation, ROCK can either directly
phosphorylate RLC or phosphorylate myosin light chain phosphatase (MLCP), inactivate
the dephosphorylating event of RLC, and thereby indirectly increase phosphorylation of
myosin RLC. NMII-A heavy chain phosphorylation carried out by casein kinase II (CK
II) or protein kinase C (PKC) separate NMII from preformed filaments and further
prevent new filament formation. Furthermore, phosphorylation of NMII-A heavy chain
by casein kinase II is also involved in blocking s100A4 binding; a protein that upon
NMII binding prevents filament formation and seems to be highly expressed in metastatic
cancers33.
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In cancer progression, altered levels of NMII isoforms, activation and related
modulators have been reported. While in some breast, colon, melanoma, and lung cancers
NMII activity correlates with metastasis and poor prognosis, in certain cancers like head
and neck, prostate, and adenocarcinomas, NMII displays a tumor suppressor role. The
variable activity of NMII in tumor progression may be attributed to the many factors that
regulate its role in migration and invasion. NMII is known to play a pivotal role in all
modes of cancer migration. In single cell migration, NMII-A mediates FA maturations in
membrane protrusions in the leading edge while NMII-B mediates adhesion turnover and
dissemination from the ECM at the back of the cell in order to thrust the cell body
forward. In amoeboid-like cell movement, NMII-based contraction stimulates actin flow
to the cell cortex which allows cancer cells to squeeze through ECM pores. In collective
migration, NMII contraction contributes to tension forces in the front of the cell which
regulates the cytoskeleton reorganization of the leading cell in order to pull the follower
cells necessary for this specific form of motility. NMII is also involved in EMT by
transducing mechanical forces to cell-cell adhesions and thereby regulating their turnover
rate32. Furthermore, NMII-mediated contraction allows cancer cells to react to the
extracellular cues and alter cytoskeleton organization for migration. Higher contractility
rendered by NMII on stiff tumor microenvironments contributes to tumor migration and
metastasis to rigid matrices like the bone36. Moreover, activation of the epidermal growth
factor receptor (EGFR) or transforming growth factor receptor β (TGFR- β) have been
shown to activate downstream molecules such as MLCK and ROCK, respectively,
thereby phosphorylating NMII isoforms and facilitating cell growth and migration32.
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Active NMII utilizes ATP to “walk” along F-actin fibers for either vascular
trafficking towards the barbed ends or formation of stress fibers. Stress fibers are made of
assemblies of 10 to 30 actomyosin bundles linked by α -actinin. In motile cells, three
main types of stress fibers are found: dorsal, ventral and transverse arcs. Dorsal stress
fibers are non-contractile, myosin free actin filament that primarily link FAs in the
lamellipodia. Transverse arcs are semi-circular myosin filaments that do not bind to FAs,
however can contract and regulate the retrograde flow towards the nucleus. Ventral stress
fibers connect FAs at both poles of the cell and their contraction at the back of the cell
stimulate retraction of the trailing edge and FA turnover. A more recently discovered type
of stress fiber is the perinuclear actin cap that regulates shape and translocation of the
nucleus (Figure1.7)37.

Figure 1.7. Stress fibers in motile cells

Rho mediated ROCK activation and MLC phosphorylation is pivotal for stress
fiber formation. ROCK aside from regulating myosin dynamics has also been observed to
activate LIMK 1 and 2 facilitating phosphorylation and deactivation of cofilin, thereby
facilitating F-actin stabilization for formation of stress fiber and actomyosin
contraction38. Although stress fiber dynamics have been investigated for decades, their
definite role in tumor cell migration is not known.
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Chapter 2. Materials and methods
2.1. Antibodies and other reagents
Antibodies directed against integrin α5 (#4705), N-cadherin (clone D4R1H), non-muscle
myosin II-A (#3403), non-muscle myosin II-B (clone D8H8), Ser19 p-NMIIRLC
(#3671), Ser1943 p-NMII-A (clone D7Z7T), Rho antibody from the Active Rho
Detection Kit (#8789), talin-1 (clone C45F1), paxillin (clone D9G12), β-actin (clone
D6A8), blebbistatin, mouse and rabbit monoclonal IgG isotypes, Alexa Fluor® 488 and
Dylight™ Phalloidin, and Alexa Fluor® 488 and 594 secondary antibodies were obtained
from Cell Signaling Technology (Danvers, MA, USA). Anti-mouse and anti-rabbit
alkaline phosphatase-labeled secondary antibodies, Alexa Fluor® 594
Deoxyribonuclease-I and the BCA protein assay reagent kit were from Thermo Fisher
Scientific (Waltham, MA, USA). The function blocking antibody against integrin
α5β1was (clone JBS5) obtained from EMD Millipore (Billerica, MA, USA) while the
anti-MyoGEF (IF: #ab22096, WB: #ab19412) and anti-non-muscle myosin II-B (clone
3H2) antibodies were purchased from Abcam (Cambridge, MA, USA). Anti-N-cadherin
antibody (clone 8C11) for immunofluorescence was obtained from Novus Biologicals
(CO, USA) while function blocking anti-N-cadherin antibody (clone GC-4) was obtained
from Sigma-Aldrich (St. Louis, MO, USA). The anti-integrin β1antibody (clone
18/CD29) was purchased from BD Biosciences (San Jose, CA, USA). The directly
labeled (Alexa Fluor® 488) polyclonal antibody against NMII-A was kindly offered by
Dr. Anne Bresnick (Albert Einstein College of Medicine, NY, USA)34. Pharmacological
inhibitor toxicity was evaluated through measurement of mitochondrial dehydrogenase
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activities with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reagent (Sigma-Aldrich).
2.2. Cell culture
The human mesenchymal breast cancer Hs578T cells and the derivative cell line
Hs578Ts(i)8 were a kind gift from Dr. S. McDonnell (UCD School of Chemical and
Bioprocess Engineering, University College Dublin, Ireland) and were grown in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (FBS), 100 IU/ml penicillin, 100 µg/ml streptomycin and 0.01 mg/ml
bovine insulin (Thermo Fisher Scientific) at 37°C equilibrated with 5% (v/v) CO2 in
humidified air. The TNBC cells used in the present study were frozen in liquid nitrogen
when not in use and were not passaged in our laboratory for >15 weeks.
2.3. Western blotting
Cell lysates were made from 80 to 90% confluent cultures using 0.5 ml lysis buffer
containing 1% Triton X-100 and 1% Halt™ Protease Inhibitor Cocktail (Thermo Fisher
Scientific). Aliquots of lysates, containing 30 µg of protein, were boiled for 5 min in
SDS-PAGE sample buffer containing 5% (v/v) β-mercaptoethanol, electrophoresed on
7.5 or 10% TGXTM precast gels and transferred to PVDF membranes (Bio-Rad
Laboratories, Hercules, CA, USA). After transfer, membranes were blocked and
incubated with relevant primary antibodies followed by incubation using alkaline
phosphatase-labeled secondary antibodies and developed using NBT/BCIP substrate
(Roche, 1:50 in 0.1 M Tris-HCl, 0.05 M MgCl2 and 0.1 M NaCl at pH 9.5). All
experiments were carried out with β-tubulin loading controls.
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2.4. Co-immunoprecipitation of cell surface molecules
Cells at 80-90% confluency, were lysed, as described under ‘Western blotting’. Lysates,
containing 1000-1500 µg protein. Antibodies to relevant cell surface molecules (1:250)
were added to the collected supernatant and rotated at 4˚C overnight. Subsequently,
protein G-Sepharose beads (Amersham Biosciences, NJ or GE Healthcare Bio-Sciences,
Pittsburgh, PA, USA) were used to recover the immunocomplexes. Immunoprecipitates
were resolved in 150 µl SDS-PAGE sample buffer and heated to 95˚C for 5 min. The
supernatants were then subjected to SDS-PAGE, transferred electrophoretically to PVDF
membranes. After transfer, the membranes were analyzed and developed as described in
‘Western blotting’.
2.5. Fluorescence immunostaining
To examine the distribution and co-localization of proteins under standard conditions,
cells were grown on glass cover slips (diameter, 12 mm) placed in 24-well plates, then
removed, washed with PBS and fixed in 4% paraformaldehyde for 1 hour (EMS,
Hatfield, PA, USA) or in methanol for 10 minutes. To examine the reorganization of
proteins upon pharmacological inhibitor treatment, 50 µM of blebbistatin was added to
cells grown on glass coverslips in a 24-well plate for 10 mins and fixed with 4%
paraformaldehyde. Next, fixed cells were washed, permeabilized with 0.1% Triton X-100
for 10 mins, blocked, and incubated with directly labeled antibodies or primary
antibodies, Alexa Fluor® 488 or 594 Phalloidin, or Deoxyribonuclease I Alexa Fluor® 594
conjugate followed by incubation with Alexa Fluor®-labeled secondary antibodies.
Stained cells were mounted with Vectashield mounting medium (Vector Labs,
Burlington, CA) and images were acquired using an Olympus IX71 fluorescence
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microscope (Tokyo, Japan) with a digital Zyla sCMOS camera and a 60X PlanApo/1.20
water objective, and in the BioTek Cytation 3 Cell Imaging Multimode reader (Winooski,
VT, USA) with a 40X or 20X objective. Control stainings were performed without
primary antibodies and with IgG isotype control antibodies to measure possible crossreaction or non-specific binding.
2.6. Wound healing assay
Cells were grown in 24-well plates until confluency and washed twice with phosphatebuffered saline (PBS). A scratch was made using a P200 pipette tip and 1 ml of medium
in the presence of DMSO, 10 uM blebbistatin or integrin α5β1 function blocking
antibody (10 ug/ml) was added. Cell migration was monitored, and images were
collected after 17 h, with an EVOS® XL Core Cell Imaging (Thermo Fisher Scientific).
ImageJ software was used to estimate the cell free area of the wounds39. The distances
over which the cells migrated were measured in three independent experiments and
expressed as percentage compared to DMSO-treated Hs578T and Hs578Ts(i)8 cells.
2.7. Cell adhesion assay
Cells were detached with 0.2% (w/v) EDTA, to avoid proteolytic degradation of cell
surface proteins, and washed with serum-free medium. Next, 5×105 cells were resuspended in 1 ml DMEM supplemented with 2% (v/v) FBS. Cell suspensions (100 µl),
in the presence or absence of function blocking antibodies (5–10 µg/ml) were added to
fibronectin pre-coated 96-well plates (BD Biosciences, San Jose, CA, USA), and
centrifuged for 1 min at 115 g. After 90 min incubation at 37°C, wells were washed four
times with PBS to remove non-adherent cells. The adherent cells were then detected and
quantified by measuring the acid phosphatase activity, through solublization of the
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remaining cells with 0.2% Triton X-100 and by the addition of the substrate, PNPP (pnitrophenyl phosphate; Sigma, St. Louis, MO, USA). Absorbance values of the lysates
were determined on a microplate reader at 405 nm (BioTek, Cytation 3, Winooski, VT,
USA) and expressed as relative absorbance (%). Mouse and rabbit IgG isotype control
antibodies were included to estimate the non-specific binding.
2.8. Cell aggregation assay
Semisolid agar pre-coated 96-well plates were prepared by adding 50 µl/well (ratio of
agar to Ringer’s salt solution in 7:1, w/v%). Single cell suspension of 10 000-100 000
cell/100 µl medium were mixed with function blocking antibodies (5-10 µg/ml) or
blebbistatin (7.5, 10 or 20 µM) and seeded onto the plate and incubated for 24 h in a
humidified atmosphere of 5% CO2 at 37°C. Aggregate formation was evaluated by phase
contrast microscopy using an EVOS® XL Core Cell Imaging System.
2.9. Flow cytometry
Cells were detached with 0.2% (w/v) EDTA, to avoid proteolytic degradation of cell
surface proteins, neutralized with cold PBS and resuspended in PBS containing 0.1%
(w/v) BSA (Sigma). Next, 2.5x105 cells were incubated with the relevant primary
antibodies for 90 min at 4°C, followed by secondary FITC or Alexa Fluor®-labeled
antibodies for 45 min at 4°C. After washing, 1x104 stained cells were analyzed for
fluorescence using the CytoFlex (Beckman CoulterÔ, Miami, FL, USA). Stainings
without primary antibodies and IgG isotype antibodies were used as controls.
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2.10. Statistics
All treatments were matched and carried out at least 3 times. Data were analyzed using
Excel, for determination of mean, standard deviation (SD) and Student's t-test (95%). The
intensity of the immunoblotted bands was quantified by densitometry, using statistical
software Scion Image (Scion Corp., Frederick, MD, USA).
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Chapter 3. Results
3.1. N-cadherin and a5b1 integrin-mediated adhesion and migration
Loss of cell-cell adhesion and changes in cell-matrix interactions are prerequisites for the
migratory and invasive behavior of cancer cells and the subsequent formation of
metastases. In the present study, the cell-cell adhesion molecule N-cadherin and cellmatrix adhesion receptor a5b1 integrin were identified as important mediators of active
adhesion processes in the in vitro Hs578T/Hs578s(i)8 cell model of triple-negative breast
cancer progression40-41. The parental Hs578T cells were found to form compact
aggregates, whereas the isogenic and invasive subclone Hs578Ts(i)8 formed less compact
and dispersed aggregates on soft agar as shown in Fig. 3.1. A (a-b) and indicate a loss of
cell-cell adhesion in the invasive variant. Since these cell lines express N-cadherins (Fig
3.1. D-E) and not the typical cell-cell adhesion mediators, E-and P-cadherin (data not
shown), the functional role of N-cadherin was determined using the function blocking Ncadherin antibody (clone GC-4). These experiments demonstrated that GC-4 interrupted
the N-cadherin homotypic ligation and aggregation of the parental Hs578T cells, forming
loose disperse aggregates while no significant changes were observed after GC-4
treatment of the invasive subclone (Fig. 3.1. A, c-d). This loss of cell-cell adhesion in
Hs578Ts(i)8 cells was found to be concomitant with increased interactions with the
fibronectin extracellular matrix protein and enhanced migration (Fig. 3.1. B-C).
Treatment with a panel of commercially available function blocking antibodies against
cell-matrix adhesion receptors identified integrin a5b1 as the sole mediator expressed in
Hs578Ts(i)8 cells to significantly reduce its interactions with fibronectin and migratory
behavior without affecting the phenotype of Hs578T cells (Fig. 3.1. B-C).
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Further investigations revealed that the total and cell surface expression levels of Ncadherin, a5, and b1 integrin subunits were higher in the parental Hs578T cells as
compared to the more invasive Hs578Ts(i)8 cells (Fig. 3.1. D-E). While these findings
contradict mainstream literature on expression levels of these adhesion molecules in
advanced breast cancer42, they support the novel idea that cadherins and integrins affect
shared cellular adhesion and signaling processes43.This possibility was tested by using the
function blocking a5b1 integrin antibody (clone JBS5) in cell-cell adhesion studies,
which indicated a significant role for cell matrix adhesion integrin a5b1 in disrupting the
cellular aggregation of Hs578T cells (Fig. 3.1. A, e-f), and was further confirmed by
reduced fibronectin interactions of Hs578Ts(i)8 cells upon blocking the cell-cell adhesion
N-cadherin with the GC-4 antibody (Fig. 3.1.B). In summary, these results indicate that
both N-cadherins and integrin a5b1 receptors are important players in the cell-cell and
cell-matrix adhesive behavior of Hs578T and Hs578Ts(i)8 cells. These findings further
support 1) the concept that integrins and cadherins work closely together and 2) the
hypothesis that N-cadherins and a5b1 integrin receptor co-organize to facilitate
cooperation and crosstalk to affect metastatic behavior.
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Figure 3.1. Function and expression of integrin α5β1 and N-cadherins in Hs578T and Hs578Ts(i)8 cell
lines. A) Cell-Cell aggregation of Hs578T (upper panel) and Hs578Ts(i)8 (lower panel) cells in the presence
of function blocking (FB) N-cadherin GC-4 (c-d) and integrin α5β1 antibodies, cultured on semi-solid agar.
B) Cell-matrix adhesion of Hs578T (closed bars) and Hs578Ts(i)8 (open bars) cell lines upon function
blocking N-cadherin and integrin α5β1. Hs578T and Hs578Ts(i)8 cells at a density of 104 cells/100 µl were
seeded in fibronectin coated 96-well plate and incubated for 90 min. The adherent cells were washed and
determined by measuring acid phosphatase activities. The interaction and adhesion are represented as
relative absorbance (%), as compared to control Hs578T cells, after subtracting non-specific binding. C)
Migration of Hs578T (closed bars) and Hs578Ts(i)8 (open bars) cell lines upon function blocking integrin
α5β1. Cells were grown in 24 well plates to confluency, scratched and incubated with normal media or
media with function blocking antibody and incubated for 17h. D) Western blots depicting total
expression levels of N-cadherin and integrin α5 and β1 subunits. E) Flow cytometry investigation of cell
surface expression levels of N-cadherin (upper panel) and integrin α5β1(lower panel) in Hs578T (closed
histogram) and Hs578Ts(i)8 (open histogram). Asterisk indicates a statistical difference in the invasive
subclone Hs578Ts(i)8 compared to the control (p<0.05). All data are averages and SD from at least 3
independent experiments.

3.2. Cross talk between integrin α5β1 and N-cadherin
To further support the concept that integrin α5β1 receptors and N-cadherins work closely
together and to test the hypothesis that their co-organization facilitates cooperation and
crosstalk, co-immunoprecipitation (IP) and immunofluorescence experiments were
performed to investigate the organization and potential interactions between these cell
surface molecules. As shown in Fig. 3.2. A, the integrin α5β1 antibody (clone JBS5) was
able to precipitate α5 and β1 integrin subunits and N-cadherins more efficiently in the
Hs578T cells than in the Hs578Ts(i)8 cell line, confirming not only the previously
detected increased expression of these subunits in the Hs578T cells, but also suggesting a
higher interaction of α5β1 integrins with N-cadherins in the parental cell line. These
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results were further verified by in immunofluorescence experiments, indicating a more
pronounced co-localization of α5β1 integrins with N-cadherins at cell-cell adhesions and
in the perinuclear area in Hs578T cells (closed arrows) as compared to the Hs578Ts(i)8
cell line (open arrows) (Figure 3.2. B). Overall, these results suggest that the loss of
organization and clustering of α5β1 integrins with N-cadherins contribute to the invasive
phenotype of Hs578Ts(i)8 cells.
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Figure 3.2. Distribution and organization of adhesive molecules in Hs578T and Hs578Ts(i)8 cell lines. A)
Co-IP experiments of integrin α5β1 stained for N-cadherin and α5 and β1 integrin subunits. Aliquots of cell
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lysate with equal amount of protein were immunoprecipitated with integrin α5β antibody and stained using
site specific anti-N-cadherin antibody by western blotting. Control membranes were developed using
antibodies targeting individual integrin α5 and β1 subunits. B) Membrane distribution of integrin α5β1 and
N-cadherin in Hs578T (solid arrows) and Hs578Ts(i)8 (open arrows) by indirect immunofluorescence.
Stronger co-localization between integrin α5β1 and N-cadherin in Hs578T cell line was seen as
demonstrated by the yellow color observed at cell-cell junction and the perinuclear area. Cells were grown
to confluency on glass cover slips, fixed with methanol for 10 mins and double stained with N-cadherin and
integrin α5β1 antibodies followed by secondary antibodies labeled with Alexa Fluor® 594 and Alexa Fluor®
488. Control stainings were performed without primary antibody and with IgG mouse and rabbit isotype
control antibodies. Scale bar, 100 µM. Experiments were performed at least 5 times.

3.3. Role of NMII in integrin-cadherin cross talk
In order to investigate the linker responsible for the observed differences in the clustering
of α5β1 integrin receptors with N-cadherins between the two cell lines, co-IPs of integrin
α5β1 receptors and N-cadherins were performed independently and stained for several
NMII proteins. Using anti-integrin α5β1 (clone JBS5), significantly increased levels of
NMII-A and NMII-B as well as the serine 19 phosphorylated NMII-RLC, needed to
activate myosin’s ATPase activity and contraction, were detected in the
immunoprecipitates of Hs578T cells, in addition to the previously determined increased
expression levels of the α5 and β1 integrin subunits (Fig. 3.3.A). These results imply a
closer connection and enhanced cooperation between different NMII proteins and
integrin α5β1 receptors in Hs578T cells as compared to the more invasive variant cell
line. This close connectivity was further visualized for integrin α5 subunits, which were
found organized in puncta that co-localized along NMII-B fibers in Hs578T (solid
arrows) and Hs578Ts(i)8 cells (open arrows) (Fig. 3.3.B). Attempts to visualize all the
observed interactions by co-IP, were not feasible due to the limited availability of
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antibodies targeting NMII-A, p-NMIIRLC and α5β1 integrin receptors suitable for
immunofluorescence and their source compatibility. Additional experiments using
phalloidin to demonstrate the presence of F-actin indicated a co-localization with integrin
α5 subunits at focal adhesions in polarized Hs578T (solid arrows) and Hs578Ts(i)8 cells,
that displayed a more fibrous F-actin pattern (open arrows) (Fig.3.3.C).
When antibodies against N-cadherins (clone D4R1H) were used for precipitation,
significantly increased levels of NMIIA and NMII-B, p-NMIIRLC (Ser19) as well as Ncadherins, were found in the Hs578T cells, using the respective antibodies for
immunostaining (Fig. 3.3.D) These findings suggest close connections and interactions
between N-cadherins and the NMII proteins and confirm the enhanced expression levels
of N-cadherin previously detected by western blotting in Hs578T cells (Fig. 3.1.D).
Fluorescent microscopy experiments revealed thick NMII-A fibers in the invasive
Hs578Ts(i)8 cells which became narrower at N-cadherin-containing cell-cell junctions
(open arrows), whereas less NMII-A fibers were observed in Hs578T cells that ended in
slightly thicker filaments at N-cadherin cell-cell junctions (solid arrows) (Fig. 3.3. E).
Immunofluorescence staining using NM-IIB showed a similar filamentous pattern in
Hs578Ts(i)8 cells and a more diffuse staining with some fiber formation at the cell edges
in the Hs578T cells (Fig. 3.3.F). Co-localization with N-cadherin was more pronounced
in the Hs578T (solid arrows) than in the Hs578Ts(i)8 (open arrows) cell lines. F-actin
staining confirmed the increased fiber formation in the invasive Hs cells, and further
demonstrated an enhanced connectivity of N-cadherin and F-actin at the cell-cell junction
of parental Hs578T cells (solid arrows) as compared to its more invasive counterpart
(open arrows) cells (Fig. 3.3.G).
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Figure 3.3. Association and localization of cell-cell and cell-matrix adhesion molecules with the
actomyosin cytoskeleton. A) Immunoprecipitates of integrin α5β1 stained for NMII-A, NMII-B and ser19
phosphorylated NMIIRLC. B) Organization of α5 integrin subunit with NMII-B fibers and C) F-actin in
Hs578T (solid arrows) and Hs578Ts(i)8 (open arrows) cell lines by indirect immunofluorescence on cells
grown on glass coverslips. D) Co-IP studies of N-cadherin stained for NMII-A, NMII-B, and ser19
phosphorylated NMIIRLC. E) N-cadherin organization with NMII-A, F) NMII-B, G) F-actin fibers in
Hs578T cells (solid arrow) and in Hs578Ts(i)8 cells (open arrows). Scale bars for B, E, F and G are 100 µm
and C is 30 µm. Experiments were performed at least 3 times.

3.4. Re-organization of cytoskeletal components in the invasive subclone
The disparity in clustering of integrin α5β1 receptors with N-cadherins and their
association with NMII proteins prompted the further investigation of the actomyosin
cytoskeletal organization in the Hs578T and Hs578Ts(i)8 cells in an effort to link these
novel findings to the changes in phenotypic behavior. Significant differences in F-actin
organization were observed between the two cell lines with distinctly thicker transverse
and dorsal fibers in polarized invasive Hs578Ts(i)8 and finer and less organized actin
filaments in the parental Hs578T cells. Consequently, increased free monomeric actin, as
G-actin, was found clustered in the perinuclear area of these cells, while less and
dispersed G-actin was seen in the Hs578Ts(i)8 cells (Fig. 3.4.A). Immunofluorescent
double stainings of NMII-A and F-actin revealed a punctate NMII-A pattern at the
leading edge of polarized Hs578T cells, whereas more NMII-A filaments were detected
in the invasive subclone, which co-localized with the prominent F-actin fibers (Fig.
3.4.B). Since actin filament assembly and turnover of focal adhesions is regulated by the
serine1943 phosphorylated form of NMII-A, its organization with F-actin was examined.
As demonstrated in Fig. 3.4.C, p-NMII-A appeared in puncta at the leading edge and in
more organized bundles at the trailing edge of the parental Hs578T cells, while a higher
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order of organization with filamentous p-NMII-A was found in close connection with Factin fibers at the leading edge of the invasive variant cell line. These results suggest the
formation and disassembly of focal adhesions at the base of the lamellipodia in the
invasive subclone provide a basis for the enhanced migratory behavior. Next, double
immunolabeling of NMII-A and NMII-B isoforms indicated significant differences with
the formation of highly organized fibers in the invasive Hs578Ts(i)8 cells as compared to
a diffuse distribution in the parental cells. It must be noted that despite their
organizational differences, NMII-A and NMII-B in both cell lines co-localize in the
posterior of the cell body and show a distinct spatial distribution with NMII-A anterior to
NMII-B in polarized cells (Fig. 3.4.D). Next, the organization of serine 19
phosphorylated NMIIRLC, which promotes cellular contraction through ATPase activity
was studied together with the NMII-B isoform. In Hs578T cells, a dispersed NMII-B
distribution was found near the cell body at the rear of the cell, while a diffuse pNMIIRLC pattern extended all the way toward the front and the lamellipodia in the
leading edge of the cells. A completely different pattern was observed in the more
invasive Hs578Ts(i)8 cells with well-defined filamentous NMII-B and posterior pNMIIRLC organization with co-localization at the ends of NMII-B fibers (Fig. 3.4.E).
These results indicate increased contractility at the trailing edge of the invasive variant
Hs578Ts(i)8, which is probably involved in the disassembly of focal adhesions at the rear
of the cell to facilitate forward movement of the cell body and stimulate migration, while
contraction at the leading edge in Hs578T cells restricts the forward movement of the cell
body thereby impeding migratory behavior.
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Figure 3.4. Organization of actin and NMII proteins. A) F-actin organization with G-actin, B) NMII-A and
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3.5. Blebbistatin mediated myosin ATPase inhibition stimulates an invasive phenotype in
Hs578T/Hs578Ts(i)8
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The distinct localization of p-NMIIRLC in Hs578T and Hs578Ts(i)8 cells indicated areas
of increased contractility through stimulated ATPase activity which could be linked to the
migratory behavior of either cell line. In the next set of experiments blebbistatin, a
reversible inhibitor of NMII ATPase activity, was used to determine the potential effects
of inhibiting NMII-mediated contractility on the adhesive and migratory behavior of the
Hs578T and Hs578Ts(i)8 cells. Prior to these experiments, the toxicity of blebbistatin was
tested using an MTT assay and no effect on cell viability was observed using
concentrations ranging from 10 to 100 µM (data not shown). Blebbistatin treatment at 20
µM resulted in a significant loss of compact cell-cell aggregation and the formation of
smaller, loose aggregates in the Hs578T cells and further disrupted the already smaller
cellular Hs578Ts(i)8 aggregates (Fig. 3.5.A). Additionally, 10 µM blebbistatin increased
not only the migratory behavior of Hs578Ts(i)8 cells with 30 % but even more effectively
of the Hs578T cells with 47%, as compared to the respective DMSO controls (Fig.
3.5.C). Visualization of the effects of blebbistatin treatment (50 µM for 10 min) on
Hs578T cells further revealed a more organized filamentous NMII-A pattern, as
compared to the punctate pattern in untreated and solvent-treated Hs578T cells, and is
comparable to NMII-A filament organization of the Hs578Ts(i)8 cells grown under
normal growth conditions (Fig.3.5.D). The changes in NMII-A filament formation upon
blebbistatin treatment were further studied in view of the actomyosin cytoskeletal
organization in Fig. 3.5.E and indicated that blebbistatin induced F-actin fiber formation
and co-localized with NMII-A in Hs578T cells, as compared to solvent-treated Hs578T
cells and was similar to the NMII-A/F-actin pattern observed in the more invasive variant
cell line.
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Additionally, the blebbistatin-mediated increase in filamentous F-actin was associated
with a reduced perinuclear monomeric G-actin distribution in Hs578T cells and was
analogous to the G-actin distribution in the invasive Hs578Ts(i)8 cells (Fig. 3.5.F). With
blebbistatin inducing a loss of cell-cell adhesion (Fig. 3.5.A) and the identification of Ncadherin as a mediator of cellular aggregation (Fig. 3.1.A, c), the effect of blebbistatin on
N-cadherin-mediated cell-cell adhesion was studied in Hs578T cells and compared to
Hs578Ts(i)8 cells. Fig. 3.5.G shows that blebbistatin decreased the localization of Ncadherin at Hs578T cell-cell junctions and reduced the organization of F-actin with Ncadherin at these sites, which is a significant difference from solvent-treated Hs578T
cells, and again similar to the N-cadherin/F-actin organization in the more invasive cells.
This further suggests that blebbistatin-induced reorganization of the cytoskeleton effects
its interactions with N-cadherins to mediate cell-cell interactions. The increased
migration of Hs578T cells upon blebbistatin treatment was further investigated by
visualizing FA-proteins, paxillin and talin-1. Results shown in Fig 3.5. H-I demonstrate
that talin-1 and paxillin-based focal adhesions in blebbistatin-treated Hs578T cells are
significantly smaller than in solvent-treated Hs578T cells and appear to be similar to
nascent talin-1 and paxillin-based focal adhesion sites in the invasive Hs578Ts(i)8
subclone. Altogether, these results indicate that blebbistatin has a major effect on the
parental cell line, stimulating an invasive phenotype similar to the Hs578Ts(i)8 cells, by
inhibiting NMII-mediated contractility necessary for Hs578T cell-cell adhesion and to
restrict their migratory behavior, by changing the actomyosin cytoskeletal organization to
alter the integrity of cell-cell junctions and FA maturation.
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Figure 3.5. Blebbistatin-induced changes in cell-cell adhesion, cell migration and actomyosin cytoskeleton
reorganization. A) Effect of blebbistatin on cell-cell aggregate formation in Hs578T (upper panel) and in
Hs578Ts(i)8 cells (lower panel) grown on semi-solid agar. B) Wound healing in the presence of blebbistatin
with quantification of migration (C, dotted bars) as compared to controls (grey bars). D) Effect of
blebbistatin treatment on NMII-A and E) F-actin fiber formation, F) G-actin and G) N-cadherin clustering,
H) talin-1 and I) paxillin-based focal adhesion formation. Cells were grown on glass coverslips to the
desired confluency, treated with 50 µM blebbistatin for 10 mins and fixed in 4% PFA prior to
immunofluorescence staining. Scale bar, 100 µm. Asterisk indicates a statistical difference in the
blebbistatin treated cells compared to respective DMSO control cells (p<0.05). All data are averages and
SD from at least 3 independent experiments.

3.6. MyoGEF mediated NMII contraction may be responsible for the phenotype of
Hs578T cells
Since the Rho family of small GTPases and related RhoGEFs have been implicated in
abnormal migratory capacity and invasion of cancer cells44,the potential role of MyoGEF,
a specific NMII related Rho regulator was studied in the Hs578T/Hs578Ts(i)8 isogenic
breast cancer progression model. Immunofluorescence microscopy experiments showed
the presence of MyoGEF at N-cadherin-mediated cell-cell interaction sites in the parental
Hs578T cells, while no such co-localization was observed in the invasive Hs578Ts(i)8
cell line (Fig 3.6.A). This close connectivity was confirmed by co-IP using a polyclonal
MyoGEF antibody, which showed significantly increased levels of MyoGEF and Ncadherin in addition to enhanced levels of p-NMII-A, NMII-B, Rho, and b-actin, in
Hs578T precipitates (Fig. 3.6.B). These findings indicate a closer connection of MyoGEF
with the previously identified N-cadherin and myosin protein interactions (Fig, 3.3.D),
Rho, and b-actin in the Hs578T cells as compared to the Hs578Ts(i)8 cells. Additional
co-IP studies with integrin α5β1 receptors further revealed a higher interaction with
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MyoGEF in Hs578T cells, relative to the more invasive subclone, Hs578Ts(i)8 (Fig.
3.6.C), which together with previous data (Fig. 3.3.A) suggests a complex formation of
MyoGEF with integrin α5β1 receptors, N-cadherins, myosin II proteins and Rho in the
parental Hs578T cells. Rho activity studies are currently underway and preliminary
results imply that active Rho in Hs578T cells is associated with NMII-A and p-MNII-A,
as well as RhoGAP, cofilin, and S100A4, a binding partner for NMII proteins and actin,
whereas active Rho in the invasive subclone is found to be connected to NMII-B, β catenin and active Src. These initial findings indicate that Rho plays an important in
adhesion and migration, and that the role of Rho and all its isoforms is ambiguous and
depends on the interacting partners and localization in the cell.
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Figure 3.6. Interaction of MyoGEF with cell-cell and cell-matrix adhesion molecules, actin cytoskeleton
and Rho GTPases. A) Immunofluorescence stainings of MyoGEF and N-cadherin in Hs578T cells (solid
arrows) as compared to the Hs578Ts(i)8 cell line. B) Immunoprecipitates of MyoGEF stained for Ncadherin, p-NMII-A, NMII-B, Rho and β-actin. C) Immunoprecipitates of integrin α5β1 stained for
MyoGEF. Aliquots of immunoprecipitates of B) MyoGEF and C) integrin α5β1 were analyzed by western
blotting using the respective antibodies and controls. Scale bar, 100 µm. Experiments were performed at
least 3 times.
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Chapter 4. Discussion
Loss of cell-cell adhesion and migration are prerequisites for the formation of
metastases. These cellular events are mediated by changes in the actomyosin
cytoskeleton. Non-muscle myosin II (NMII) belongs to the myosin superfamily of motor
proteins, which binds to actin and controls actin cross-linking and contraction. While it is
recognized that NMII is fundamental in cell adhesion and migration, its role and
regulation in these processes is not fully understood.
This study provides new insight into the role of NMII in the organization of cell
membrane components to regulate cell adhesion and migration in the Hs578T triplenegative breast cancer cell line and its more invasive subclone Hs578Ts(i)8. This isogenic
cell line pair embodies an elegant in vitro cell model system to study metastatic TNBC
and eliminates confounding results due to the use of different TNBC cell lines or
actomyosin cytoskeletal rearrangements induced by mutant approaches41.
This study is the first to demonstrate that the association and clustering of Ncadherins and a5b1 integrin receptors with NMII isoforms, NMII-A, and NMII-B, are
essential for the maintenance of functional cell-cell adhesion complexes and prevents
migration. We propose a model of N-cadherin/integrin a5b1 organization held together
by NMII-A and B as a possible mechanism for regulating adhesion and motility of
Hs578T TNBC cells.
An initial major finding from our study was that decreased expression levels of Ncadherins and integrin a5b1 receptors were associated with increased adhesive behavior
toward fibronectin and loss of cell-cell adhesion in the more advanced Hs578Ts(i)8 cell
line as compared to its less invasive counterpart Hs578T. These findings challenge the
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concept of epithelial-mesenchymal transition, in which increased expression levels of Ncadherin correlate with enhanced cellular invasion45-46, and on the other hand support the
recent suggestion, by Mui et al., that cadherins and integrins cooperate to stimulate
adhesion43. This newer concept gained strength in our study when function blocking of
a5b1 integrin receptors was found to inhibit cell-cell adhesion and anti-N-cadherins
reduced cell-matrix interaction which indicated a cooperation and was further confirmed
by the association between a5b1 integrin receptors and N-cadherins in the parental Hs
cell line. These results also contribute to the growing evidence that cadherin-based cellcell junctions contain integrin complexes, similar to focal adhesions, which seems to be
of particular importance in cancer and tissue morphogenesis47-49. While novel
compelling evidence on crosstalk between integrin α5β1 and N-cadherin is provided,
the possibility that other integrin receptors or cadherins are involved is likely and is
beyond the scope of this study.
A fundamental group of molecules in cellular adhesion and migration is the
myosin superfamily of motor proteins, which regulates adhesion and transport of cargo
to the lamellipodia for the formation of protrusive structures through their contractile
activity 50. In this study, it was demonstrated that NMII-A and NMII-B isoforms act as
molecular linkers between integrin α5β1 and N-cadherin to maintain functional cell-cell
adhesion complexes in Hs578T cells, as such a molecular arrangement was not
significantly present in the more invasive Hs578Ts(i)8 subclone. In addition, the active
form of myosin, p-NMIIRLC was also found to be highly associated with α5β1 integrin
receptors and N-cadherins in the less invasive Hs578T cells. Interestingly, F-actin was
found in thicker fibers in the invasive Hs578Ts(i)8 subclone, which aligned with p-
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NMII-A fibers at the leading edge of the cell while a higher order of filamentous NM-II
B and p-NMIIRLC organization appeared at the trailing edge. These observations were
strikingly different in the parental Hs578T cells, where p-NMII-A was found in puncta
at the leading edge and in more organized bundles at the trailing edge and p-NMIIRLC
extended all the way toward the leading edge of the cells. Since p-NMII-A is involved
in focal adhesion formation and turnover and p-NMIIRLC in contraction, these results
suggest a role for NMII in the formation of focal adhesions at the base of the
lamellipodia, disassembly at the rear of the cell to facilitate forward movement of the
cell body, and stimulation of migration of the invasive Hs578Ts(i)8 cells. While in
Hs578T cells, contraction at the leading edge restricts the forward movement of the cell
body and thereby impedes its migratory behavior. Additionally, this spatial arrangement
of active NMII and F-actin pattern together with the observed increase in G-actin
accumulation in the perinuclear area in the parental Hs578T cells support the fact that
active NMII cells stimulates the actin retrograde flow. This flow of actin monomers
moving in towards the nucleus from the leading edge of the cell not only prevents the
formation of actin-rich protrusions but also reduces the rate of migration49.
The active role of NMII in contraction and actin polymerization and protrusion
formation was further confirmed by using blebbistatin, the pharmacological inhibitor of
NMII ATPase activity. Blebbistatin treatment induced increased migration and loss of
cell-cell adhesion, most effectively in Hs578T cells and was associated with significant
morphological changes and F-actin extensions (data now shown). These results are in
agreement with results reported by Zhenan Lui et al51, in which diminished NMII
activity was found to promote migration in wound healing experiments, impair
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contraction on collagen gel and decrease the amount of vinculin-based focal adhesions.
Blebbistatin also disturbed the clustering of N-cadherin and induced the formation of
small, nascent focal adhesions in parental Hs578T, which further strengthened our
findings that NMII activity is needed to maintain the integrity of N-cadherin-mediated
cell-cell adhesion and for the maturation into strong focal contacts. These findings are
in line with previous studies reporting that blebbistatin reduced E-cadherin clustering
which decreased their cell-cell adhesive behavior52 and did not affect the formation of
initial ECM adhesive contacts53. The latter study also indicated that NMII activity is
required for the maturation of focal contacts into stable ECM adhesions and
corresponds with the larger focal adhesions composed of talin-1 and paxillin observed
in the parental Hs578T cell line.
From our results it is evident that there is a link between NMII and cell adhesion
molecules and that NMII activity controls adhesion and migration. Additionally, studies
on NMII imply that its activity can also be regulated through activation of intracellular
Rho49. The Rho family of GTPases consists of a growing number of isoforms each with
similar or distinct roles in cancer cell migration and invasion. While these findings
make it difficult to define their exact roles, it must be mentioned that many of these
studies do not take in account the spatial distribution and neglect their involvement in
other cellular processes as cell cycle regulation and cell division 54. Determining a
potential role for Rho and its isoforms in the regulation of NMII activity was explored
by studying MyoGEF, an important regulator of Rho signaling pathways. In the
parental cells, MyoGEF was found to significantly interact with N-cadherin, integrin
α5β1 receptors, Rho, and the actomyosin cytoskeleton and indicates that Rho could be
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active at the cell-cell junctions of Hs578T cells. In MDA-MB-231 TNBC cells,
MyoGEF has been shown to work together with NMII-A in the front of the cell to
establish cell polarity and mediate invasion through activation of RhoA/RhoC55.
While this study is vague on the mechanism of action of MyoGEF in metastatic
TNBC, our findings propose that MyoGEF negatively influences the migration of the
parental Hs578T cells. This conclusion is further supported by preliminary results
demonstrating increased association of cofilin and phosphorylated cofilin with GTPbound Rho (data not shown) in the parental Hs cells, which may result from
phosphorylation by LIMK1/2. Cofilin is thought to sever actin filaments and facilitate
protrusive structure formation whereas overactive cofilin has been shown to reduce cell
migration by disturbing the LIMK/cofilin dynamics which further fortifies the effects of
inactive phosphorylated cofilin56.
These preliminary data together with the previously described observed NMII
activity in contraction and retrograde flow, could indicate an organization of key
mediators to impair actin organization and reduce the migratory capacity in the Hs578T
cell line relative to the more invasive subclone.
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Chapter 5. Conclusions
This study provides new insight into the role of NMII to regulate and control cancer cell
adhesion and migration. We document for the first time that organization and clustering
of N-cadherins and α5β1 integrin receptors in the cell membrane and their association
with NMII-A and NMII-B, are required for functional cell-cell adhesions. This multicomponent complex stimulates NMII activity to maintain cellular aggregation and
restricts migration presumably by increasing contraction at the leading edge and
enhancing the actin retrograde flow, resulting in less polymerized and organized F-actin
at the leading edge or in protrusions. Disruption of this complex or inhibition of NMII
activity results in loss of cell-cell adhesion and stimulates migration. The decreased
activity of NMII correlates with F-actin polymerization and formation of highly
organized F-actin and myosin fibers with actin-rich protrusions and more nascent
adhesive complexes while reducing N-cadherin and α5β1 integrin receptor clustering at
cell-cell junctions. Altogether, these findings demonstrate that NMII and NMII activity
link N-cadherin and integrins to the actomyosin cytoskeleton to control and maintain
stable cell-cell adhesion complexes.
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APPENDIX 1
5,6,7,3',4',5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells
via suppression of MAPK and Akt signaling pathways and arresting cell cycle
A.1.1 Abstract
Natural components continue to be an important source for the discovery and
development of novel anticancer agents. Polymethoxyflavones are a class of flavonoids
found in citrus fruits and medicinal plants used in traditional medicine. In the present
study, the anticancer activity of the well-known nobiletin (5,6,7,8,3',4'hexamethoxyflavone) was compared against its less studied structural isomer
5,6,7,3',4',5'-hexamethoxyflavone. These compounds were evaluated on the Hs578T
triple-negative breast cancer cell line and its more migratory subclone Hs578Ts(i)8.
5,6,7,3',4',5'-hexamethoxyflavone was found to be less toxic than nobiletin, while a
similar growth inhibitory effect was observed after 72 h. Additionally, 5,6,7,3',4',5'hexamethoxy flavone arrested the cell cycle in the G2/M phase, while no effect was
observed on apoptosis or the migratory behavior of these cells. Furthermore, mechanistic
studies revealed that the growth inhibition was concomitant with reduced
phosphorylation levels of signaling molecules in the MAPK and Akt pathways as well as
cell cycle regulators, involved in regulating cell proliferation, survival and cell cycle. In
summary, the present study is the first to report on the anticancer activities of
5,6,7,3',4',5'-hexamethoxy flavone and to provide evidence that this flavone could have a
greater potential than nobiletin for prevention or treatment of triple negative breast
cancer.
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A.1.2 Introduction
Compounds derived from natural products play an important role in the discovery
of clinically suitable therapeutic agents. This is particularly true for anticancer medicines,
with almost 70% of the novel anticancer drugs approved, over the past six decades,
coming from natural products or based on the knowledge gained from natural products57.
Recently, a renewed interest for flavonoids as anticancer agents has been catalyzed by
flavopiridol (Alvocidib), a potent cyclin-dependent kinase (CDK) inhibitor, which has
been granted orphan drug designation by the FDA in 2014 to treat patients with acute
myeloid leukemia58. Flavonoids are found throughout the plant kingdom and several
eepidemiological studies suggest that dietary intake of flavonoids is responsible for
chemoprevention59. Of particular interest are the polymethoxyflavones (PMFs), flavones
substituted with two or more methoxy groups. This subclass of flavonoids is thought to
be superior to polyhydroxylated flavonoids due to their increased metabolic stability, oral
bioavailability and consequently improved cancer chemopreventive activities60.
PMFs can be found in high concentrations in the peel of several Citrus species and in
medicinal plants used in traditional medicine61-63. Studies on the anticancer activity of
PMFs have mostly been focused on nobiletin. This 5,6,7,8,3′,4′-hexamethoxyflavone has
been shown to be effective in vitro and in vivo by affecting several cellular activities,
including inhibition of cell proliferation, invasion and migration, inducing cell cycle
arrest as well as reducing angiogenesis, signaling pathways and bioactivation by CYP16467

. Notable also, is its predominant anticancer activity in MDA-MB-468 cells which

indicates a potential role of nobiletin for the prevention of triple negative breast cancer
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(TNBC)68, an aggressive and highly metastatic subtype with poor prognosis for which
hormonal therapy is not beneficial and chemotherapy remains the only treatment69.
Studies with different Citrus species and medicinal plants indicate a high
structural variability in PMF content, including the presence of smaller methoxyflavones
and structural isomers. While several reports suggest that the anticancer activity from
flavonoids is profoundly affected by their composition and structure, limited studies are
published on the effect of these less known congeners60, such as 5,6,7,3’,4’,5’hexamethoxyflavone. This flavone has the same structural formula as nobiletin and has
been isolated from Citrus reticulate and Ageratum conyzoides (Figure S.1.1).

Figure S.1.1 Structures of hexamethoxyflavones: 5,6,7,3’,4’,5’-hexamethoxyflavone and nobiletin

The compound was found to be cytotoxic against P-388 mouse leukemia cells, but not
against the HT-29 human colon adenocarcinoma cell line and to suppress the
degranulation from antigen-stimulated rat basophil RBL-2H3 cells through its effect on
signaling as Syk/PLCg’s/PKC and mitogen-activated protein kinase (MAPK) pathways
and Ca2+ influx70-71.
The present study aimed at investigating the possible anticancer effects of 5,6,7,3’,4’,5’hexamethoxyflavone and comparison against the well-studied nobiletin in the Hs578T
progression model of TNBC. This in vitro cell system comprises the Hs578T TNBC cell
line and its more metastatic and isogenic variant Hs578Ts(i)8 and embodies an elegant
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experimental model for studying the anticancer activity of both hexamethoxyflavones in
TNBC and on TNBC progression41.
A.1.3 Materials and methods
A.1.3.1. Antibodies and other reagents
Antibodies directed against p-ERK (D13.14.4E), p-JNK/SAPK (81E11), p-Akt (D9E), pp38 MAPK (D3F9), p-Chk2 (C13C1), p-Chk1 (133D3), p-Cdc2 (10A11) and anti-β-actin
(D6A8) or β-tubulin (9F3) antibodies as well as camptothecin were from Cell Signaling
Technology (Danvers, MA, USA). Anti-mouse and anti-rabbit alkaline phosphataselabeled secondary antibodies, the BCA protein assay reagent kit and Trypan Blue
solution were from Thermo Fisher Scientific (Waltham, MA, USA). Drug toxicity was
evaluated through measurement of mitochondrial dehydrogenase activities with 3-(4,5Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) reagent (Sigma, St.
Louis, MO, USA). Nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone were obtained from
Alkemist Labs (Costa Mesa, CA, USA).
A.1.3.2. Cell culture
The human mesenchymal breast cancer Hs578T cells and the derivative cell line
Hs578Ts(i)8 were a kind gift from Dr. S. McDonnell (UCD School of Chemical and
Bioprocess Engineering, University College Dublin, Ireland)41 and were grown in
DMEM-medium supplemented with 10% (v/v) FBS, 100 IU/ml penicillin, 100 µg/ml
streptomycin and 0.01 mg/ml bovine insulin (Thermo Fisher Scientific) at 37˚C
equilibrated with 5% (v/v) CO2 in humidified air. The TNBC cells used in this study were
frozen in liquid nitrogen when not in use and were not passaged in our laboratory for >15
weeks.
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A.1.3.3. Assay for cell viability
The effect of nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone on cell viability was
tested in accordance with Romijn et al.72. Briefly, mitochondrial dehydrogenase activities
were measured by an MTT-reagent. Cells were seeded in 96-well plates at an initial
density of 1.5x104 cells in 100 µl culture medium. After overnight incubation, cells were
treated with nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone at a final concentration of
100, 50 and 10 µM. After 24 and 72 h incubation, 100 µl medium was removed prior to
the addition of MTT-reagent and formed formazan crystals were dissolved in 200 µl
DMSO. Four independent experiments were completed to determine the mean
absorbance referring to cell viability, using a Cytation 3 Cell Imaging Multi-mode Reader
with Gen5 software (BioTek, Winooski, VT, USA) and were expressed in percentage as
compared to DMSO-treated control cells. In each experiment, eight wells were used per
condition.
A.1.3.4. Cell counting
Cells were seeded in 25 cm2 culture flasks at an initial density of about 1.5x105 cells in 5
ml culture medium and were treated with nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone at a final concentration of 100 µM after overnight incubation. The
cells were allowed to grow for 24, 48 and 72 h, harvested using trypsin/EDTA and
counted with a TC20TM automated cell counter (Bio-Rad Laboratories, Hercules, CA,
USA). At least three independent experiments were performed to determine the mean
value, which is presented as a percentage as compared to the DMSO-treated controls.
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A.1.3.5. Wound healing assay
Cells were grown in 24-well plates until confluency and washed twice with PBS. A
scratch was made using a P-200 pipette tip and 1 ml of medium in the presence of
DMSO, nobiletin or 5,6,7,3’,4’,5’-hexamethoxyflavone at 100 µM, was added. Cell
migration was monitored, and images were collected after 17 h, with an EVOS XL Core
Cell Imaging (Thermo Fisher Scientific). ImageJ software was used to estimate the cell
free area of the wounds. The distances over which the cells migrated were measured in
three independent experiments and expressed as percentage compared to DMSO-treated
Hs578T and Hs578Ts(i)8 cells.
A.1.3.6. Proteome Profiler Human Phospho-kinase Array
Cells at 70% confluency were washed three times, serum-starved overnight, washed
again and stimulated for 2 h with complete culture medium, followed by a treatment of
10 min with 100 µM nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone prior to cell lysis.
Lysates were made using kit components and the array experiments were performed
following the manufacturer's instructions (R&D Systems, Inc., Minneapolis, MN, USA).
Briefly, aliquots of cell lysates, containing 250 µg of protein, were incubated overnight
with a human phospho-kinase array membrane containing capture antibodies against 43
different kinase phosphorylation sites. After washing, the membranes were incubated
with biotinylated antibodies, streptavidin-HRP and chemiluminescent reagent for
detection of phosphorylated protein at each capture spot on the membranes. Images were
taken with a Licor Odyssey Fc and analyzed with Image Studio 5.0 (LI-COR
Biosciences, Lincoln, NE, USA) for determination of mean pixel density and further
analyzed using Excel.
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A.1.3.7. Western blotting
70% confluent cell cultures were washed three times and for MAPK and Akt signaling
experiments serum-starved overnight, washed again and stimulated for 2 h with complete
culture medium prior to treatment with 100 µM nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone for indicated times. For investigation of cell cycle regulators, 70%
confluent cultures were not stimulated and washed three times. Subsequently, cells were
lysed using lysis buffer containing 1% Triton X-100 and 1% Halt™ Protease Inhibitor
Cocktail (Thermo Fisher Scientific). Aliquots of lysates containing 25-30 µg of proteins
were boiled for 5 min in SDS-PAGE sample buffer supplemented with 5% bmercaptoethanol, electrophoresed on 10% or 4-15% gradient Mini-PROTEAN® TGXTM
gels and transferred to PVDF membranes (Bio-Rad Laboratories). After transfer,
membranes were incubated with relevant antibodies against p-ERK, p-JNK/SAPK, p-p38
MAPK, p-Akt, p-Chk2 and Chk1, p-Cdc2 and b-tubulin or b-actin, as loading controls,
followed by incubation with a secondary alkaline-phosphatase anti-rabbit antibody and
stained with NBT/BCIP (1:50 in 0.1 M Tris-HCl, 0.05 M MgCl2 and 0.1 M NaCl at
pH 9.5).
A.1.3.8. Flow cytometry analysis
Cells were treated for 72 h with 100 µM nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone. Floating cells and trypsinized adherent cells were combined and
washed with cold PBS or cell culture medium. For detection of apoptosis, cells were
stained with an Annexin-V/7AAD kit (Beckman Coulter, Miami, FL, USA) using the
manufacturers’ protocol. In brief, cells were incubated with Annexin V and 7-AAD in
ice-cold binding buffer in the dark. After 15 min the samples were mixed with more
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binding buffer and analyzed within 30 min. Positive controls for apoptosis induction
included Hs578T and Hs578Ts(i)8 cells treated with 10 µM camptothecin for 72 h. Cell
cycle analysis was investigated by adding Vybrant® DyeCycle™ Green Stain (Thermo
Fisher Scientific) to 1 ml cell suspension at a final concentration of 250 nM. After 30 min
incubation at 37°C, the samples were analyzed by flow cytometry and compared against
DMSO-treated cells. All these experiments were performed on a CytoFLEX flow
cytometer (Beckman Coulter) using CytExpert 2.0 software.
A.1.3.9. Statistics
All treatments were matched and carried out at least 3 times. Data were analyzed using
Excel, for determination of mean, standard deviation (SD) and Student's t-test (95%). The
intensity of the immunoblotted bands was quantified by densitometry, using statistical
software Scion Image (Scion Corporation, Frederick, MD, USA).
A.1.4 Results
A.1.4.1. Effect of nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone on cell viability
Hs578T and the more invasive Hs578Ts(i)8 cells were treated for 24 and 72 h with nobiletin
and 5,6,7,3’,4’,5’-hexamethoxyflavone at concentrations of 10, 50 and 100 µM, and
cytotoxicity was determined by the MTT-test. The effects of these compounds on cell
viability are shown in Table S.I. Overall, the compounds did not have a major toxic effect
toward the cell viability of the tested cell lines at 100 µM, after 24 and 72 h and
consequently no IC50 values could be determined. Instead, nobiletin generally reduced the
cell viability of the Hs578T and Hs578Ts(i)8 cell lines with approximately 30% after 24 h
and 30 to 50% after 72 h at its highest concentration, while no noteworthy effect was
observed for 5,6,7,3’,4’,5’-hexamethoxyflavone after 24 h (upper panel), and a small drop
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after 72 h (lower panel). Interestingly, we found that both nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone at 100 µM showed a greater toxicity toward the more invasive
Hs578Ts(i)8 variant cell line, decreasing the cell viability to 51.6 and 68.1% respectively,
after 72 h.
Table S.1. Percentage of cell viability of Hs578T and Hs578Ts(i)8 after 24 treatments.

A.1.4.2. Nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone inhibit cell growth
The growth inhibitory effects of the compounds at 100 µM were evaluated after 24, 48 and
72 h by cell counting. Nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone markedly inhibited
the growth of Hs578T (Figure. S.1.2.A) and Hs578Ts(i)8 cells (Figure S.1.2.B) in a timedependent manner. After 24 h, limited effects were observed. After 48 and 72 h, however,
nobiletin significantly reduced the amount of cells by roughly 40 and 50%, respectively.
The growth inhibition following 5,6,7,3’,4’,5’-hexamethoxyflavone treatment was most
pronounced after 72 h and reached a level (~50%) almost similar to nobiletin. It should be
noted, that the reduction in number of cells grown in the presence of nobiletin is relatively
comparable to the data obtained in the MTT-assays (Table AI), which may suggest a
confounding effect due to its effect on cell viability.
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Figure S.1.2. Growth inhibitory effects on Hs578T (A) and Hs578Ts(i)8 cells (B) after treatment with 100
µM nobiletin (closed bars) and 5,6,7,3’,4’,5’-hexamethoxyflavone (open bars). The number of cells was
determined by counting and expressed as mean % ± SD of three independent experiments with n=3 per
condition in each experiment. *Statistical difference from DMSO-treated control cells (p<0.05).

A.1.4.3. Nobiletin and cell migration
In our previous study, we published that the Hs578Ts(i)8 cells migrate twice as fast as
compared to the parental Hs578T cells in a wound healing assay under normal growth
conditions40, which was in line with the earlier published increased migratory capacity of
the more invasive Hs578Ts(i)8 cell line using the BD MatrigelTM Invasion Chamber assay
system41. Herein, we tested the potential of nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone to inhibit the migratory behavior, and this particularly of the
Hs578Ts(i)8 cells. Results shown in Figure S.1.3 reveal that nobiletin at a concentration
of 100 µM significantly reduced the migration by 40%, and that there was no selectivity
toward the more migratory and invasive Hs578Ts(i)8 cells. In contrast, no effect was seen
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for 5,6,7,3’,4’,5’-hexamethoxyflavone and the wound was closed after 17 h, similar to the
DMSO-control conditions. Yet again, the effect of nobiletin should be viewed with
caution, as the growth inhibitory activity may confound the effect of nobiletin on cellular
migration.

Figure S.1.3. Effects on wound healing after 17 h treatment with 100 µM nobiletin (closed bars) and
5,6,7,3’,4’,5’-hexamethoxyflavone (open bars). % closure of wound, resulting from measuring the difference
in width at t=0 and t=17, are expressed as mean % ± SD of three independent experiments, with n=6 per
condition in each experiment. *Statistical difference from DMSO-treated control cells (p<0.05).

A.1.4.4. Effect of nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone on apoptosis
Annexin V-FITC/7-AAD double staining was used to examine the effect of the two
hexamethoxyflavones on the induction of cellular apoptosis. There are several compounds
available to induce apoptosis in cancer cells in studies, in vitro. In vivo, taxanes have been
shown to be beneficial in neoadjuvant, adjuvant, and metastatic settings in TNBC73, and
this specifically toward the basal-like (BL) 1 and 2 TNBC subtypes as compared to the
mesenchymal-like

and

luminal

androgen

receptor

subtypes74.

Since

the

Hs578T/Hs578Ts(i)8 breast cancer model represents mesenchymal-like TNBC, the wellknown and universally used inducer of apoptosis, camptothecin, was used. While the
addition of camptothecin in a final concentration of 5 to 10 µM and incubation in a time
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range of 4 to 24 h usually allows the evaluation of apoptosis in many cell lines, Hs578T
and Hs58Ts(i)8 cells did not respond to the treatment within that time frame or after 48 h
(data not shown). Instead, camptothecin-induced apoptosis was observed after 72 h at a
concentration of 10 µM. Consequently, Hs578T and Hs578Ts(i)8 cells were exposed to
nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone for 72 h, and floating cells and adherent
cells were combined prior to staining. Figure S.1.4.A and the quantification in S.1.4.B
indicate no significant differences in the Annexin V-FITC positive and 7-AAD positive or
negative cells after 72 h treatment with nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone at
a final concentration of 100 µM as compared to DMSO and this in both cell lines. These
results suggest that Hs578T and Hs578Ts(i)8 cells i) are quite resistant toward
camptothecin-induced apoptosis, and ii) do not undergo apoptosis after exposure to
nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone (Figure S.1.4.A and B).

Figure S.1.4. Effects of 100 µM nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone, as well as 10 µM
camptothecin treatment for 72 h on apoptosis, in Hs578T (upper panel) and Hs578Ts(i)8 cells (lower panel).
(A) Cells were trypsinized, combined with floating cells prior to staining with Annexin V-FITC/7-AAD.
Profiles are representative examples of four independent experiments. (B) % of live (open bars), early
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apoptotic (light grey bars), late apoptotic (grey bars) and necrotic (closed bars) cells, expressed as mean % ±
SD of four independent experiments.

A.1.4.5. Nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone inhibit activation of distinct
signaling molecules
With increasing knowledge on and complexity of signaling pathways as well as the fact
that these pathways are highly cell-type specific, phospho-kinase arrays were performed
alongside Western blotting, to take an unbiased approach for analysis of affected
signaling molecules and pathways upon treatment with the two hexamethoxyflavones.
This was particularly important, given the uniqueness of the cell model system and the
limited information available. Initially, Western blotting was performed to determine an
approximate optimal time point in the cell lines used, for nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone-mediated inhibition of phosphorylated ERK and Akt. The
phosphorylation of these two signaling molecules is often found to be elevated after
hormone or growth factor stimulation and inhibited following exposure to PMFs, such as
nobiletin and tangeretin64, 75. Limiting factors to use this approach include the fact that
these cell lines are triple negative and the poor comprehension of the importance of
growth factors in the behavior of the Hs578T and more migratory and invasive
Hs578Ts(i)8 cells. The MAPK and Akt pathways are known to be activated by a variety
of factors, among them receptor tyrosine kinases, integrin, cytokine and G-protein
coupled receptors. Therefore, the method of overnight serum-starvation and serum
stimulation was applied to achieve phosphorylation and demonstrate inhibition by
nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone. Responsiveness to serum stimulation,
after overnight serum-starvation, with complete culture media was tested over time and 2
h proved to be an optimal stimulus, while a significant inhibition of the two
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hexamethoxyflavones could be observed as early as about 5 to 10 min after treatment,
with 10 min used in the subsequent array experiments.
The phospho-kinase array revealed a considerable amount of information, with most
notably the decrease of p-ERK phosphorylation by nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone as compared to DMSO-treated cells. A similar trend was observed
for

p-JNK1/2/3, although the effect

was less pronounced. Moreover, both

hexamethoxyflavones inhibited the phosphorylation levels of Akt, while the
phosphorylation of checkpoint kinase 2 (Chk2) seemed to be solely reduced upon 10 min
nobiletin treatment. Additionally, phosphorylated p38 MAPK was only detected in the
Hs578T cell line and was inhibited by the two hexamethoxyflavones (HMFs) (Figure
S.1.5.A and B), while it was below the detection limit of the array for the Hs578Ts(i)8 cells.
It must be mentioned that only two arrays per cell line and per component were performed
to obtain initial data. Even though these arrays would allow for the quantification of the
relative phosphorylation levels, the obtained results were further confirmed by Western
blotting in kinetics experiments in Hs578T (Figure S.1.5.C) and Hs578Ts(i)8 (S.1.5.D)
cells. Serum stimulation induced the phosphorylation of all kinases as compared to
unstimulated cells, except for Chk2. Chk2 was not only found highly phosphorylated in
these cell lines after serum-starvation but also under normal growth conditions (data not
shown). Nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone were able to inhibit the seruminduced phosphorylation of ERK, SAPK/JNK and Akt in a time range of 5 to 20 min in
Hs578T and Hs578Ts(i)8 cells. Additionally, significant Chk2 phosphorylation inhibition
was evident for nobiletin after 5 min, whereas 5,6,7,3’,4’,5’-hexamethoxyflavone
significantly reduced the phosphorylation levels after treatments of 20 min and longer.
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Also, in the Western blotting experiments, phosphorylated p38 MAPK could only be
clearly detected in the Hs578T cells under the experimental conditions used, and was
reduced by nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone over the investigated time
range (Figure S.1.5.C and D).
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Figure S.1.5. Upper panel: (A) Effect of a 10 min treatment with 100 µM nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone, after overnight serum-starvation and stimulation for 2 h with complete culture media,
on kinase phosphorylation sites using phospho-kinase arrays in Hs578T (upper panel) and Hs578Ts(i)8 cells
(lower panel). (B) Quantification by mean pixel density, expressed as means of % inhibition of nobiletin
(closed bars) and 5,6,7,3’,4’,5’-hexamethoxyflavone (open bars) in Hs578T and Hs578Ts(i)8 cells vs DMSOtreated cells. Results were obtained from 2 independent experiments.
Lower panel: Western blot analysis of phosphorylated proteins in Hs578T (C) and Hs578Ts(i)8 cells (D).
Cells were serum-starved overnight, stimulated with complete culture medium for 2 h and treated for
indicated times with 100 µM nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone. Cell lysates were analyzed by
TGXTM gels, transferred to PVDF membranes and use of the corresponding primary antibodies against kinase
phosphorylation sites and tubulin as loading controls. Blots are representative examples of at least three
independent experiments. Scion Image densitometry analysis of bands comparing the relative levels of
phosphorylation after 10 min 100 µM nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone as compared to
DMSO-treatment. Bar graphs are means ± SD from at least three independent experiments. *Statistical
difference from DMSO-treated cells (p<0.05). ND: not detected.

A.1.4.6. Nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone affect the cell cycle
As a result of the significant nobiletin- and 5,6,7,3’,4’,5’-hexamethoxyflavone-mediated
inhibition of Chk2 phosphorylation in the previous phosphokinase arrays and Western blot
experiments, the effect of both hexamethoxyflavones on the cell cycle was evaluated by
performing a Vybrant® DyeCycle™ Green staining. Comparison with DMSO-treated cells
indicated that both hexamethoxyflavones upon treatment with 100 µM for 72 h, but not 48
h (data not shown), were able to cause a slight increase in G2/M arrest (Figure S.1.6.A and
B). While 5,6,7,3’,4’,5’-hexamethoxyflavone elevated the subpopulation of Hs578T and
Hs578Ts(i)8 cells by 16.1 and 13.4% respectively, nobiletin only significantly enhanced
the G2/M arrest in Hs578T cells by 14.3%. Western blot results in Figure S.1.6.C and D
revealed that Chk2 phosphorylation at T68 decreased after 10 min in the presence of
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nobiletin (p<0.05) and 30 min with 5,6,7,3’,4’,5’-hexamethoxyflavone (p<0.05), without
prior serum-starvation and stimulation, in both cell lines. Additionally, Chk1
phosphorylation levels were below or near the detection limit in the Hs578T cell lines,
whereas weak levels were detected in the more invasive variant, which were not notably
altered in the presence of the HMFs. Furthermore, phosphorylation levels of Cell division
cycle 2 (Cdc2), known as CDK1, which acts downstream from Chk1 and regulates G2/M
arrests, were found significantly decreased after 30 min exposure to nobiletin and
5,6,7,3’,4’,5’-hexamethoxyflavone in the Hs578T and after 30 to 60 min in Hs578Ts(i)8
cells (p<0.05).

Figure S.1.6. Effects on the cell cycle after treatment with 100 µM nobiletin and 5,6,7,3’,4’,5’hexamethoxyflavone for 72 h in Hs578T (upper panel) and Hs578Ts(i)8 cells (lower panel). (A) Cells were
trypsinized, combined with floating cells prior to staining with Vybrant® DyeCycle™ Green. Profiles are
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representative examples of four independent experiments. (B) % of population in sub G0 (open bars), G0/G1
(light grey bars), S (grey bars) and G2/M (closed bars) cells, expressed as mean % ± SD of three independent
experiments. *Statistical difference from DMSO-treated cells (p<0.05). Lower panel: Western blot analysis
of phosphorylated Chk2 and Cdc2 in Hs578T (C) as well as Chk1 in Hs578Ts(i)8 cells (D). Cells were treated
for indicated times with 100 µM nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone. Cell lysates were analyzed
by TGXTM gels, transferred to PVDF membranes and use of the corresponding primary antibodies against
kinase phosphorylation sites and b-actin as loading controls. Blots are representative examples of at least
three to five independent experiments. Scion Image densitometry analysis of bands comparing the relative
levels of phosphorylated p-Chk2 (solid line) and p-Cdc2 (dashed line) in Hs578T cells as well as p-Chk1
(dotted line) in Hs578Ts(i)8 cells, after 100 µM nobiletin (closed circles) and 5,6,7,3’,4’,5’hexamethoxyflavone (open circles) as compared to DMSO-treatment. Line graphs are means ± SD from three
to five independent experiments.

A.1.5 Discussion
This study reports for the first time on the anticancer activity of 5,6,7,3’,4’,5’hexamethoxyflavone. This polymethoxyflavone is a structural isomer of 5,6,7,8,3’,4’hexamethoxyflavone, known as nobiletin. They differ in the position of one methoxy group
either on ring A or B (Fig. 1). While nobiletin is widely studied and known for its beneficial
effects on cancer cells, 5,6,7,3’,4’,5’-hexamethoxyflavone is not, despite being isolated
from the same sources and the recognized concept of isomerism affecting biological
activity60, 69, 71, 76.
In the present study, we used the Hs578T/Hs578Ts(i)8 breast cancer progression model4041

for several reasons, including the potential role of nobiletin against TNBC68 and in

prevention of metastasis64-66. Our results indicated that 5,6,7,3’,4’,5’-hexamethoxyflavone
is less toxic than nobiletin against Hs578T and Hs578Ts(i)8 cells, while exerting a nearly
similar effect as nobiletin in the cell counting experiments after 72 h treatments.
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Additionally, only nobiletin reduced the migratory behavior with almost 40% within 17 h
in both cell lines. The effects of nobiletin on cell viability are in the same range as
previously published studies using MCF-7, T47D, MDA-MB-231 and SKBR3 breast
cancer cells. Interestingly, these studies also reported that nobiletin reduced the migratory
behavior of MCF-7 cells by 40% in wound-healing experiments and invasion by 30% using
the matrigel invasion assay, while a 60% reduction in invasion was observed in MDA-MB231 cells77-78. These findings as well as the observations presented in this study should be
interpreted and used with caution, given that nobiletin decreased the cell viability and
number of cells by 20 to 30% within 24 h which may confound the effect on migration and
invasion. This idea is confirmed by the fact that 5,6,7,3’,4’,5’-hexamethoxyflavone did not
influence migration, while showing limited to no effect on cell viability and cell counts
after 24 h. Other structural congeners with methoxy groups at position 3’,4’,5’ of the Bring include sinensetin and 5,6,7,8,3',4',5'-heptamethoxyflavone. Unfortunately, few
studies are published on the potential anticancer activity of the structurally related pentaand heptamethoxyflavone. A recent study suggested that sinensetin has an antiproliferative
effect and the ability to induce apoptosis at concentrations of 50 µM and higher79. These
results are quite remarkable given the poor solubility in water and the typical solvents as
DMSO, ethanol or methanol and consequently questions the validity of the results.
Further investigations on the possible mechanisms of action of 5,6,7,3’,4’,5’hexamethoxyflavone and nobiletin resulting in a decreased number of cells suggested that
72 h treatments with either compounds were not able to induce apoptosis in the Hs578T
and Hs578Ts(i)8 cells as compared to camptothecin. It must be mentioned though that
nobiletin studies are controversial and inconclusive when it comes to its effect on
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apoptosis. One reasoning could be that certain cell lines, such as the Hs578T cell line and
its more invasive variant Hs578Ts(i)8 as well as glioma cell lines64 are more resistant to
apoptosis, and that nobiletin or other PMFs are not potent enough to induce an apoptotic
effect similar to camptothecin.
The use of Proteome Profiler Human phospho-kinase arrays allowed for an objective
screening of altered phosphorylation levels of 43 different kinases. The array data as well
as the confirming Western blotting results, using pathway activation and potential
inhibition as described by Shapiro80, revealed that 5,6,7,3’,4’,5’-hexamethoxyflavone
treatment mainly inhibited MAPK and Akt signaling pathways, recognized for influencing
cell proliferation, cell differentiation, and cell death. These findings were comparable to
nobiletin and were also obtained without pathway stimulation for which a significant
inhibition was detected after 30 min exposure to both hexamethoxyflavones (data not
shown). Numerous studies link the effect of nobiletin to the inhibition of MAPK and Akt
signaling pathways and the small non-receptor tyrosine kinases involved. This study
contributes to this knowledge and adds TNBC cell lines to the list, while the effect of
5,6,7,3’,4’,5’-hexamethoxyflavone on signaling is novel and puts this flavone in a similar
group as nobiletin and tangeretin, as potential chemopreventive or therapeutic agent.
Additionally, both hexamethoxyflavones reduced the phosphorylation levels of cell cycle
checkpoint kinase 2 (Chk2) and induced a subtle arrest at G2/M in the TNBC cell lines.
Usually, Chk2 is phosphorylated at T68 after DNA damage, such as ionizing radiation and
UV irradiation, however in the Hs578T/Hs578Ts(i)8 cell model high phosphorylation
levels were seen in untreated or solvent treated conditions, which suggests that repair
mechanisms are constitutively active in these cells. Furthermore, several reports indicate
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that Chk2 induces a cell cycle arrest at G1/S and G2/M81. Our results do not show a G1/S
arrest, instead the hexamethoxyflavones cause a G2/M arrest. This outcome is in contrast
to the G1/S arrest of nobiletin on MDA-MB-468 TNBC cells reported by Chen et al.68.
However, our study included not only the effect on G2/M but also Chk2 phosphorylation
and is supported by previous studies in which particularly Chk2 was proven to be required
for the G2/M arrests triggered by naturally occurring chemopreventive agents82. On the
other hand, G2/M arrests typically dependent on a Chk1-associated signaling pathway
leading to the inhibition of Cyclin B1/Cdc2 activity, with Cdc2 also known as cyclin
dependent kinase 1 (CDK1). Chk1 is activated by phosphorylation on S345 and
subsequently inhibits Cdc25C phosphatase by phosphorylating S216. This Cdc25C plays
an important role in the dephosphorylation and activation of CDK1/Cdc2 on T14/Y15
needed for G2/M transition83-84. In this study, Chk1 phosphorylation was difficult to detect
in the Hs578T, whereas very weak levels were observed in Hs578Ts(i)8 cells. Nobiletin
and 5,6,7,3’,4’,5’-hexamethoxyflavone did not seem to significantly affect the
phosphorylation levels of Chk1, while the phosphorylation of Cdc2 was found to be
suppressed after 30 min and more, which suggests that both hexamethoxyflavones induce
the activation of Cdc2 needed for G2/M transition. These results are not in accordance with
the observed G2/M arrest, thus it seems that Chk1 and Chk2 may have additional roles in
the nobiletin and 5,6,7,3’,4’,5’-hexamethoxyflavone-mediated G2/M arrest. Interestingly,
these observations are not uncommon, several groups have demonstrated a G2/M cell cycle
arrest following the use of herbal derivatives. These studies mentioned that the mechanism
of G2/M arrest may be secondary to antimitotic effects in contrast to checkpoint
modulation late in G285. Furthermore, research using flavopiridol or silibinin with other
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chemotherapeutic agents showed increased cytotoxicity associated with G1 and G2 arrests,
while flavopiridol is known to mediate its effect via inhibition of cdks, silibinin in
combination with doxorubicin was found to decrease the expression of Cdc25C and Cdc2
85

.These correlations hint that down-regulation of G2/M cell cycle regulators resulting in

increased G2/M arrest could be a mechanism as well. Further investigations will be needed
to clarify the mechanisms of G2/M arrest and determine whether nobiletin and
5,6,7,3’,4’,5’-hexamethoxyflavone have an antimitotic effect on the Hs578T and
Hs578Ts(i)8 cells or suppress cell cycle regulators.
In conclusion, our results indicate that 5,6,7,3’,4’,5’-hexamethoxyflavone has several
anticancer properties and could be a more valuable component than nobiletin. This initial
study showed that 5,6,7,3’,4’,5’-hexamethoxyflavone is less toxic than nobiletin, and
shows comparable growth inhibition of TNBC cells. This effect could be ascribed in part
to a suppression of MAPK and Akt signaling pathways and to the induction of a G2/M cell
cycle arrest. Taken together, the present results suggest that 5,6,7,3’,4’,5’hexamethoxyflavone may possess potential as a novel preventive or therapeutic agent in
the treatment of TNBC.
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